Physician profile
Edwin Jonathan Guzman
NPI 1881290252
$4,079.60
in general payments reported to CMS, 2019-2025
18 companies · $2,456 in 2025
The $2,456 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $38.74 · 2023: $60.02 · 2024: $1,525 · 2025: $2,456.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,929 · Education: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,928.69 |
| Education | $112.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $762.88 | 2024-2025 | Opzelura, Opzelura |
| Janssen Biotech, INC. | $675.45 | 2024-2025 | Tremfya |
| Arcutis Biotherapeutics, INC. | $665.02 | 2024-2025 | Zoryve |
| Abbvie INC. | $521.00 | 2023-2025 | |
| Organon LLC | $323.30 | 2022-2025 | Vtama, Nexplanon |
| Genzyme Corporation | $264.56 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $169.43 | 2024-2025 | Dupixent, Libtayo |
| Ucb, INC. | $153.14 | 2024-2025 | Bimzelx |
| Dermavant Sciences, INC. | $146.00 | 2024 | Vtama |
| Astrazeneca Pharmaceuticals LP | $121.89 | 2024 | Airsupra |
| Verrica Pharmaceuticals INC. | $107.45 | 2024-2025 | Ycanth |
| Galderma Laboratories, L.P. | $60.48 | 2025 | Nemluvio |
| Novartis Pharmaceuticals Corporation | $22.56 | 2023 | |
| Amgen INC. | $21.79 | 2023 | Otezla |
| Leo Pharma INC. | $19.01 | 2025 | Adbry |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $16.35 | 2024 | Sotyktu |
| Pfizer INC. | $16.12 | 2024 | |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edwin Guzman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.